Purpose: Comparing a GnRH agonist and an antagonist protocol for IVF/ICSI with regard to
1. frequency of ovarian hyperstimulation syndrome (OHSS) (1. outcome measure)
2. quality of life (2. outcome measure)
3. live birth rate (2. outcome measure)
4. gene expression profiles of granulosa and cumulus cells, and concentrations of estradiol
and vascular endothelial growth factor in follicular fluid(not only compared between
GnRH agonist and antagonist protocol, but also between patients with OHSS and no OHSS
and patients becoming pregnant and not becoming pregnant (2. outcome measure), and
5. number of oocytes removed per treatment, number of embryo transfers per treatment and
number of spontaneous abortions per treatment (these three parameters are tertiary
outcome measures).
In addition to the above mentioned efficacy outcome measures the safety outcome measure
"frequency of known side-effects" will be compared between the two protocols.